Written by:
Andreas Lysandropoulos, MD, PhD, Franchise Head, Neurosciences, Ophthalmology, and Rare Diseases, Parexel
Alzheimer’s disease drug development has reached an inflection point, and the challenge it presents is not only scientific but structural. Today, many therapies that have cleared regulatory hurdles are failing to reach patients at scale because health care providers and payers often remain unconvinced of their real-world benefit. Approval, as it turns out, is not the finish line.
Closing the gap between scientific achievement and meaningful patient access requires more than innovative molecules or biomarkers. It requires the infrastructure, expertise, and long-term partnership that can orchestrate extraordinary complexity at scale. This is where Alzheimer’s disease has become a proving ground for a fundamentally different Contract Research Organization (CRO) model, one built on the understanding that success depends on every segment —sponsors, sites, regulators, payers, and patients — doing their part. When that circle functions, the result is not just improved trial execution. It is the foundation for therapies to actually reach the people who need them most.
Why Alzheimer’s Disease Is a Stress Test for Clinical Development
Alzheimer’s disease presents the most demanding combination of scientific uncertainty and operational complexity in clinical development today. The amyloid and tau hypothesis underling recently approved therapies continues to face credible scientific debate, and that uncertainty can shape every development decision that follows.
Further, Alzheimer’s disease is most often identified after significant progression, especially in communities where cognitive decline is still widely mistaken for normal aging.
This detection gap means that people most underserved by the diagnostic system are frequently the same ones most absent from clinical trials, with direct consequences for both the science and the equity of access to its benefits.
High screening failure rates strain budgets and timelines in ways that put entire programs at risk. While emerging screening approaches and blood-based biomarkers are beginning to address this, the problem remains one of the most operationally costly in clinical research. Trials run for years because detecting meaningful cognitive decline requires time. Patients deteriorate over that period, placing mounting pressure on caregivers and trial retention alike.
In turn, the condition demands CRO expertise at its deepest level, including full real-time understanding and connection with the indication-specific site universe with its multi-level complexities.
The Measurement Problem Remains the Elephant in the Room
Apart from whether currently used endpoints can capture meaningful changes for patients, one underappreciated failure mode in Alzheimer’s disease trials is rater variability, the inconsistency introduced when cognitive assessments are administered differently across sites and geographies.
Addressing this requires institutional knowledge of sites, rigorous rater certification, and continuous real-time monitoring of data quality to conduct rapid retraining when scoring drift appears. It also requires managing rater continuity. Staff turnover is a predictable event that demands contingency plans, because an undertrained replacement mid-trial can introduce variability into the dataset before anyone notices. The ability to identify outlier signals at a specific site and respond quickly, retraining rather than waiting for a scheduled monitoring visit, is what keeps data quality intact across the full length of a complex, multi-year program.
In a field where the difference between a successful trial and a failed one can come down to the consistency of a single scored assessment, that capability provided by CROs is not a support function. It is a core scientific contribution.
Technology and Real World Evidence (RWE) Promise
While rater oversight addresses the human variability in how data is collected, Alzheimer’s disease trials face an equally significant challenge in how patients participate, particularly across multi-year timelines. This is where digital tools, including eCOA platforms, wearables, and home-based monitoring, offer the potential to reduce site visit burden and extend trial participation to patients and their caregivers who might otherwise be unable to sustain the demands of a traditional model.
Experience in other neurological conditions such as epilepsy, where continuous home EEG monitoring has been widely theorized but frequently rejected by patients, illustrates the gap between what is scientifically sound and sustainable. The appropriate path is phased adoption, digital endpoints introduced as exploratory measures in earlier-phase studies with the evidence base built deliberately before elevating these tools into further study.
At the same time, RWE-focused CROs can uniquely support AD drug development by generating and analyzing real-world data to complement clinical trials—informing patient stratification, disease progression models, and comparative effectiveness, while also strengthening regulatory and payer submissions by providing evidence on long-term outcomes, safety, and healthcare utilization in routine clinical practice.
Here, the CRO’s role is not simply to adopt available technology, but to support selection, integration, and operationalization of tools in ways that regulators, sites, and patients trust.
The Case for Earlier Partnership
Managing measurement precision and technology integration are both areas where CRO expertise adds value during trial execution. But the most consequential contribution a CRO can make in Alzheimer’s disease development often happens before the trial begins, sometimes before the protocol even exists.
While traditional models position CROs primarily as execution partners engaged once the design is fixed, this leaves significant value unrealized. Institutional knowledge built across many programs — knowing which sites consistently deliver on their recruitment promises, which endpoints hold up under regulatory and payer scrutiny, and how early-phase data should be structured to support credible later stage trials — is knowledge that accumulates, and that CROs are uniquely positioned to bring to the table. This experience also builds something harder to quantify but equally consequential, regulatory confidence. Agencies recognize consistency, and a CRO that has navigated multiple programs with rigorous, reproducible practices brings a track record that can meaningfully shape credibility during regulatory interactions when it matters most.
Early engagement also creates conditions to better design trials around the lived realities of patients and caregivers, rather than asking them to adapt to the trial. In Alzheimer’s disease especially, caregivers are essential partners in a process that often spans years, during which patient’s conditions change and participation demands compound. Trials need to be built with that trajectory in mind. And a CRO engaged before the protocol is set can advocate for design choices before burdens accumulate and retention becomes a problem to manage rather than something anticipated.
Completing the Circle
Each of these actions function as part of an interconnected system. Yet, that system only works when all of its members are acting in partnership: sponsors with scientific vision, sites with clinical relationships, regulators with rigorous frameworks, payers with standards that ensure value, and patients and caregivers with the willingness to participate.
Around this circle, the CRO’s contribution is to make sure the system holds, that rigorous science, operational discipline, and genuine partnership with sites and patients translate into evidence that health systems and families can trust. Not every program will succeed. But every program should be built with the understanding that patients are waiting, because they are.